Influenza A virus (IAV) and secondary bacterial infections (SBI) are responsible for a significant number of illnesses and deaths each year. Management of these diseases is difficult, in part due to a lack of understanding of complex interplay of host-pathogen interactions and inability to study pneumonia in clinical settings. To advance the goal of developing effective therapeutics and predicting IAV and SBI risk, new microbiologic tools that can assess how host immune responses work to limit viral burden and enhance bacterial invasion in quantitative detail is essential. This project addresses gaps in immunological knowledge of IAV and SBIs and gaps in developing predictive models and interpreting infection data by using a tandem mathematical-experimental approach to quantify alveolar macrophage loss (Aim 1) and SBI related type I interferon exacerbation (Aim 2). These studies will exploit the predictive models to establish the intricate feedbacks in these responses, identify controlling parameters and dynamics that govern different clinical outcomes, improve interpretation of immunological and clinical data, and reveal new targets for treatment and prevention of influenza and related bacterial infections.
Influenza A Virus infection and the bacterial infections that complicate influenza pose considerable public health threats by causing widespread morbidity and mortality. Advancing the availability of effective therapeutic agents to combat disease is necessary, but knowledge of how the host immune responses are regulated and work to control the pathogens is limited. The objective of the proposed research is to quantify the effect of two innate immune responses in limiting viral burden, enhancing disease, and facilitating bacterial invasion during influenza by developing and validating novel predictive mathematical models.
